About: Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We analyzed a group of 190 patients who underwent ASCT at our clinic for multiple myeloma as primary therapy in years 1995–2008. The assessment of the best therapeutic effect of ASCT showed the total rates of patients with complete remission – 22%, very good partial remission (VGPR)– 8%, partial remission – 63%, stabilized disease – 6% and progression – 1%. The transplant related mortality (TRM) was 4.1%. With the median follow-up of surviving patients 2.6 years, the median progression-free survival (PFS) and overall survival (OS) were 21 and 54 months, respectively; the likelihood of a 7-year OS was 28%. Comparing tandem versus single transplants, there was a significant increase in the median PFS, however, there was no difference in OS. The IVE mobilization regimen was found to be more efficacious than high dose cyclophosphamide. We analyzed a group of 190 patients who underwent ASCT at our clinic for multiple myeloma as primary therapy in years 1995–2008. The assessment of the best therapeutic effect of ASCT showed the total rates of patients with complete remission – 22%, very good partial remission (VGPR)– 8%, partial remission – 63%, stabilized disease – 6% and progression – 1%. The transplant related mortality (TRM) was 4.1%. With the median follow-up of surviving patients 2.6 years, the median progression-free survival (PFS) and overall survival (OS) were 21 and 54 months, respectively; the likelihood of a 7-year OS was 28%. Comparing tandem versus single transplants, there was a significant increase in the median PFS, however, there was no difference in OS. The IVE mobilization regimen was found to be more efficacious than high dose cyclophosphamide. (en)
Title	Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre (en)
skos:prefLabel	Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre (en)
skos:notation	RIV/00064165:_____/10:7927!RIV11-MZ0-00064165
http://linked.open...avai/riv/aktivita	I Z
http://linked.open...avai/riv/aktivity	I, Z(MSM0021620808)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2011
http://linked.open...aciTvurceVysledku	Pohlreich, David Kořen, Jan Trněný, Marek Špička, Ivan Pytlík, Robert Vacková, Blanka Straub, Jan
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Všeobecná fakultní nemocnice v Praze / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	285109
http://linked.open...ai/riv/idVysledku	RIV/00064165:_____/10:7927
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Multiple myeloma; High dose therapy; ASCT; Tandem ASCT (en)
http://linked.open.../riv/klicoveSlovo	Multiple myeloma ASCT High dose therapy Tandem ASCT
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[1436BB52C10E]
http://linked.open...i/riv/nazevZdroje	Prague Medical Report
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	2010
http://linked.open...iv/tvurceVysledku	Pytlík, Robert Trněný, Marek Pohlreich, David Špička, Ivan Trnková, Marie Vacková, Blanka Straub, Jan Kořen, Jan
http://linked.open...n/vavai/riv/zamer	Molekulárně biologické, genetické a epigenetické aspekty vzniku a rozvoje modelových tumorů dospělého věku. Význam pro epidemiologii, časnou diagnostiku a léčbu
issn	1214-6994
number of pages	12 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software